From the metabolic syndrome to the concept of global cardiometabolic risk;A metabolikus szindrómától a kardiometabolikus kockázat fogalmáig

Orvosi Hetilap

Volumn 150, Issue 18, 2009, Pages 821-829

  Nádas, Judit ^a,b   Jermendy, György ^a  

^a Fovarosi Önkormanyzat Egyesitett Szent Istvan es Szent Laszlo Korhaz Rendelointezet   (Hungary)

^b NONE   (Hungary)

Author keywords

Cardiometabolic risk; Cardiovascular risk factors; Diabetes mellitus; Insulin resistance; Metabolic syndrome

Indexed keywords

ABDOMINAL OBESITY; ARTICLE; ASIAN; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLUSTER ANALYSIS; DEVELOPING COUNTRY; DYSLIPIDEMIA; GLUCOSE INTOLERANCE; HUMAN; HYPERTENSION; INSULIN RESISTANCE; METABOLIC SYNDROME X; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE;

ABDOMINAL FAT; CARDIOVASCULAR DISEASES; DEVELOPED COUNTRIES; DEVELOPING COUNTRIES; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; GLUCOSE INTOLERANCE; HUMANS; HYPERTENSION; INSULIN RESISTANCE; METABOLIC SYNDROME X; PREDICTIVE VALUE OF TESTS; PREVALENCE; RISK FACTORS; WAIST CIRCUMFERENCE;

EID: 66749166063     PISSN: 00306002     EISSN: 17886120     Source Type: Journal    
DOI: 10.1556/OH.2009.28606     Document Type: Article

References (56)

1. Reaven, G. M.: Role of insulin resistance in human disease. Banting lecture 1988. Diabetes, 1988, 37, 1595-1607.
2. Halmos T., Jermendy Gy.: Metabolikus x-szindróma az ezredfordulón. (Elméleti vonatkozások és gyakorlati teendok). Orv. Hetil., 2000, 141, 2701-2709.
3. Jermendy Gy.: Miért lett a centrális típusú elhízás a metabolikus szindróma nemzetközi diagnosztikai kritériumrendszerének alapveto eleme? Metabolizmus, 2006, 4, 51-56.
4. Definition, diagnosis and classification of diabetes mellitus and its complications. Report of a WHO consultation. Part 1: Diagnosis and classification of diabetes mellitus. World Health Organization, Geneve, 1999.
5. Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults: Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA, 2001, 285, 2486-2497.
6. A Nemzetközi Diabetes Társaság (IDF) ajánlása a metabolikus szindróma világszerte érvényes defi níciójára (szöveghu magyar fordítás). Diabetologia Hungarica, 2005, 13, 107-112.
7. Sawicki, P. T., Baba, T., Berger, M. és mtsa: Normal blood pressure in patients with insulinoma despite hyperinsulinemia and insulin resistance. J. Am. Soc. Nephrol., 1992, 3, S64-68.
8. Halmos T., Kautzky L., Suba I.: A metabolikus szindróma koncepciójának története - az atheroszklerózis kialakulásának patomechanizmusa. Metabolizmus, 2004, Suppl A5-10.
9. Meigs, J. B., Rutter, M. K., Sullivan, L. M. és mtsai: Impact of insulin resistance on risk of type 2 diabetes and cardiovascular disease in people with metabolic syndrome. Diabetes Care, 2007, 30, 1219-1225.
10. Liao, Y., Kwon, S., Shaughnessy, S. és mtsai: Critical evaluation of adult treatment panel III criteria in identifying insulin resistance with dyslipidemia. Diabetes Care, 2004, 27, 978-983.
11. Jermendy Gy.: A 2-es típusú diabetes világméretu terjedésének okai és következményei. LAM, 2006, 16, 105-113.
12. Sierra-Johnson, J., Johnson, B. D., Allison, T. G. és mtsai: Correspondence between the adult treatment panel III criteria for metabolic syndrome and insulin resistance. Diabetes Care, 2006, 29, 668-672.
13. Maison, P., Byrne, C. D., Hales, C. N. és mtsai: Do different dimensions of the metabolic syndrome change together over time? Evidence supporting obesity as the central feature. Diabetes Care, 2004, 24, 1758-1763.
14. Palaniappan, L., Carnethon, M. R., Wang, Y. és mtsai: Predictors of the incident metabolic syndrome in adults: The Insulin Resistance Atherosclerosis Study. Diabetes Care, 2004, 27, 788-793.
15. Janssen, I., Katzmarzyk, P. T., Ross, R.: Waist circumference and not body mass index explains obesity-related health risk. Am. J. Clin. Nutr., 2004, 79, 379-384.
16. Bigaard, J., Tjonneland, A., Thomsen, B. L. és mtsai: Waist circumference, BMI, smoking, and mortality in middle-aged men and women. Obes. Res., 2003, 11, 895-903.
17. Ford, E. S., Giles, W. H., Dietz, W. H.: Prevalence of the metabolic syndrome among US adults: findings from the Third National Health and Nutrition Examination Survey. JAMA, 2002, 287, 356-359.
18. Ford, E. S.: Prevalence of the metabolic syndrome defi ned by the International Diabetes Federation among adults in U.S. Diabetes Care, 2005, 28, 2745-2749.
19. Qiao, Q., DECODE Study Group: Comparison of different definitions of the metabolic syndrome in relation to cardiovascular mortality in European men and women. Diabetologia, 2006, 49, 2837-2846.
20. Széles, G., Szigethy, E., Vokó, Z. és mtsai: The epidemiology of metabolic syndrome in the Hungarian adult population: a representative survey (abstract). Diabetes, 2007, 56, A626.
21. Nádas, J., Putz, Z., Fövényi, J. és mtsai: Cardiometabolic risk and educational level in adult patients with type 1 diabetes. Acta Diabetologica, 2008 Oct 9. [Epub ahead of print].
22. Cull, A. C., Jensen, C. C., Retnakaran, R.: Impact of the metabolic syndrome on macrovascular and microvascular outcomes in type 2 diabetes mellitus. Circulation, 2007, 116, 2119-2126.
23. Tong, P. C., Kong, A. P., So, W. Y. és mtsai: The usefulness of the International Diabetes Federation and the National Cholesterol Education's Adult Treatment Panel III defi nitions of the metabolic syndrome in predicting coronary heart disease in subjects with type 2 diabetes. Diabetes Care, 2007, 30, 1206-1211.
24. Jermendy, G., Hetyési, K., Bíró, L. és mtsa: Prevalence of the metabolic syndrome in hypertensive and/or obese subjects. Diabetic Med., 2004, 21, 805-806.
25. Nádas, J., Putz, Z., Fövényi, J. és mtsai: Cardiovascular risk factors characteristic for the metabolic syndrome in patients with type 1 diabetes. Exp. Clin. Endocrin. Diab., 2009, 117, 107-112.
26. Thorn, L. M., Forsblom, C., Fagerudd, J. és mtsai: Metabolic syndrome in type 1 diabetes: association with diabetic nephropathy and glycemic control (the FinnDiane study). Diabetes Care, 2005, 28, 2019-2024.
27. Metascreen Writing Committee: The metabolic syndrome is a risk indicator of microvascular and macrovascular complications in diabetes. Results form Metascreen, a multicenter diabetes clinic-based survey. Diabetes Care, 2006, 29, 2701-2707.
28. Davis, T. M., Bruce, D. G., Davis, W. A.: Prevalence and prognostic implications of the metabolic syndrome in community-based patients with type 1 diabetes: the Fremantle Diabetes Study. Diab. Res. Clin. Pract., 2007, 78, 412-417.
29. Reindel, J., Zander, E., Heinke, P. és mtsai: The metabolic syndrome in patients with type 1 diabetes mellitus: Associations with cardiovascular risk factors and cardiovascular morbidity. Herz, 2004, 29, 463-469.
30. Pambianco, G., Costacou, T., Orchard, T. J.: The prediction of major outcomes of type 1 diabetes: a 12-year prospective evaluation of three separate definitions of the metabolic syndrome and their components and estimated glucose disposal rate: the Pittsburgh Epidemiology of Diabetes Complications Study experience. Diabetes Care, 2007, 30, 1248-1254.
31. Kahn, R., Buse, J., Ferrannini, E. és mtsa: The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia, 2005, 48, 1684-1699.
32. Reaven, G. M.: The metabolic syndrome: is this diagnosis necessary? Am. J. Clin. Nutr., 2006, 83, 1237-1247.
33. Grundy, M. S.: Does the metabolic syndrome exist? Diabetes Care, 2006, 29, 1689-1692.
34. Lee, J., Ma, S., Heng, D. és mtsa: Should central obesity be an optional or essential component of the metabolic syndrome?: Ischemic heart disease risk in the Singapore Cardiovascular Cohort Study. Diabetes Care, 2007, 30, 343-347.
35. Lorenzo, C., Serrano-Ríos, M., Martínez-Larrad, M. T. és mtsai: Is waist circumference an essential component of the metabolic syndrome? Diabetes Care, 2007, 30, 2141-2142.
36. Kadota, A., Hozawa, A., Okamura, T. és mtsai: Relationship between metabolic risk factor clustering and cardiovascular mortality stratified by high blood lucose and obesity. Diabetes Care, 2007, 30, 1533-1538.
37. Oda, E.: The metabolic syndrome as a concept of adipose tissue disease. Hypertens. Res., 2008, 31, 1283-1291.
38. Lakka, H. M., Laaksonen, D. E., Lakka, T. A. és mtsai: The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA, 2002, 288, 2709-2716.
39. Laaksonen, D. E., Lakka, H. M., Niskanen, L. K. és mtsai: Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested defi nitions of the metabolic syndrome in a prospective cohort study. Am. J. Epidemiol., 2002, 156, 1070-1077.
40. Ford, E. S.: Risk for all cause mortality, cardiovascular diasease, and diabetes associated with the metabolic syndrome. Diabetes Care, 2005, 28, 1769-1778.
41. Ford, E. S., Schulze, M. B., Pischon, T. és mtsai: Metabolic syndrome and risk of incident diabetes: fi ndings from the European Prospective Investigation into Cancer and Nutrition-Potsdam Study. Cardiovasc. Diabetol., 2008, 12, 7-35.
42. Eberly, E. L., Prineas, R., Cohen, J. D. és mtsai: Metabolic syndroma - Risk factor distribution and 18-year mortality in the multiple risk factor intervention trial. Diabetes Care, 2006, 29, 123-130.
43. Wang, J., Routsalainen, S., Moilanen, L.: Metabolic syndrome and incident end-stage peripheral vascular disease: A 14-year follow-up study in elderly Finns. Diabetes Care, 2007, 30, 3099-4005.
44. Gami, A. S., Witt, B. J., Howard, D. E. és mtsai: Metabolic syndrome and risk of incident cardiovascular events and death: a syste matic review and meta-analysis of longitudinal studies. J. Am. Coll. Cardiol., 2007, 49, 403-414.
45. Ford, E. S., Chaoyang, L., Naveed, S.: Metabolic syndrome and incident diabetes: Current state of the evidence. Diabetes Care, 2008, 31, 1898-1905.
46. Lorenzo, C., Williams, K., Hunt, K. J. és mtsai: The National Cholesterol Education Program-Adult Treatment Panel III, International Diabetes Federation, and World Health Organization Defi nitions of the Metabolic Syndrome as Predictors of Incident Cardiovascular Disease and Diabetes. Diabetes Care, 2007, 30, 8-13.
47. Sattar, N., McConnachie, A., Shaper, A. és mtsai: Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies. Lancet, 2008, 371, 1927-1936.
48. Stern, M. P., Williams, K., Gonzalez-Villalpando, C. és mtsai: Does the metabolic syndrome improve identification of individuals at risk of type 2 and/or cardiovascular disease? Diabetes Care, 2004, 27, 2676-2681.
49. McNeill, A. M., Rosamond, W. D., Girman, C. J. és mtsai: The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. Diabetes Care, 2005, 28, 385-390.
50. Girman, C. J., Rhodes, T., Mercuri, M. és mtsai: The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am. J. Cardiol., 2004, 93, 136-141.
51. Kilpatrick, E. S., Rigby, A. S., Atkin, S. L.: Insulin resistance, the metabolic syndrome, and complication risk in type 1 diabetes: "double diabetes" in the Diabetes Control and Complications Trial. Diabetes Care, 2007, 30, 707-712.
52. Kahn, R.: Metabolic syndrome - what is the clinical usefulness? Lancet, 2008, 371, 1892-1894.
53. Després, J. P., Lemieux, I.: Abdominal obesity and metabolic syndrome. Nature, 2006, 444, 881-887.
54. Brunzell, J. D., Davidson, M., Furberg, C. D. és mtsai: Lipoprotein Management in Patients With Cardiometabolic Risk - Con- sensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care, 2008, 31, 811-822.
55. Gaede, P., Vedel, P., Larsen, N. és mtsai: Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N. Engl. J. Med., 2003, 348, 383-393.
56. Jermendy Gy.: A szív- és érrendszeri betegségek kockázatát csökkento terápia késoi hatásai. A kardiometabolikus terápiás memória hipotézise. LAM, 2008, 18, 459-466.